Crohn's disease and ulcerative colitis (inflammatory bowel disease, IBD) involve chronic intestinal inflammation driven by aberrant immune responses to commensals and barrier dysfunction.
Crohn's disease and ulcerative colitis (inflammatory bowel disease, IBD) involve chronic intestinal inflammation driven by aberrant immune responses to commensals and barrier dysfunction. Current therapies (aminosalicylates, corticosteroids, biologics) suppress inflammation but do not repair underlying mucosal defects or fully restore immune tolerance. Stem cell strategies exploit the immunoregulatory capacity of placental mesenchymal stem cells (MSCs), which secrete anti-inflammatory cytokines (IL-10, TGF-β) and promote regulatory T cell differentiation. MSCs also enhance barrier integrity by supporting tight-junction proteins and promoting mucosal healing. A particularly important development: darvadstrocel, an allogeneic MSC product, recently obtained European Union conditional approval for treatment of complex perianal Crohn's fistulae—marking the first regulatory recognition of cell therapy for IBD. Beyond this niche indication, systemic MSC therapy for induction remission and maintenance is investigational across 89 registered trials globally; thirteen actively recruit.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €20,000–€27,500 (dvcstem.com) |
| Principalele tipuri de celule studiate | MSC de la membrana amniotică |
| Statutul aprobării | Parțial aprobat |
| Studii înregistrate (ClinicalTrials.gov) | 89 · 13 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Darvadstrocel (Alofisel) received EU conditional marketing authorisation in 2018 for complex perianal fistulising Crohn's disease refractory to conventional and biologic therapy. Pivotal trials reported fistula healing (absence of drainage from all treated fistulae) in 50–55% of patients at 24 weeks, versus ~30% in sham controls. This remains the only EU-approved cell therapy for IBD. For systemic induction therapy, published trials of intravenous MSC infusion in active Crohn's or ulcerative colitis report clinical remission in 40–55% at 8–12 weeks, comparable to biologic induction but with longer onset (8–12 weeks versus 2–4 weeks for TNF inhibitors). Mucosal healing (endoscopic resolution of ulceration) is less frequently achieved than symptom remission. Long-term maintenance data are sparse; re-induction or re-infusion protocols are emerging.
Depending on assessment, a Crohn's & IBD protocol may draw on:
Darvadstrocel for perianal fistulae costs approximately €7,000–9,500 per application in European centres. Systemic MSC induction therapy for active Crohn's or ulcerative colitis costs €6,000–8,000 per infusion protocol. Multiple fistulae or combined induction+maintenance regimens escalate costs to €12,000–20,000+ per year. Insurance coverage varies significantly: EU approved indication (perianal fistulae) is reimbursed by several national healthcare systems (Spain, France, Germany) with prior authorisation; systemic IBD remission therapy is rarely covered, classified as investigational. Out-of-pocket payment is standard for non-fistula indications.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Crohn's & IBD cost-by-country breakdown, or compare the best countries for Crohn's & IBD →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Crohn's & IBD.
FAQ complet Boala Crohn și IBD → · Defalcare costuri Boala Crohn și IBD →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită